Published 2 days ago • loading... • Updated 2 days ago
Deadline Fast Approaching for Canadians to File Claims in Class-Action Drug Suit
Canadians have a deadline of August 27 to file claims in a $4.75 million class-action settlement regarding the drug Rexulti, which is used to treat schizophrenia and depression.
The Quebec Superior Court approved the settlement in November after authorizing the national class action against Otsuka Canada Pharmaceutical Inc. and Lundbeck Canada Inc..
The class action includes Canadians prescribed Rexulti since February 2017 who developed compulsive behaviors or impulse-control disorders such as gambling, shopping, or binge-eating.
Affected individuals may receive settlements ranging from about $6,500 for mild cases to over $102,000 for more severe cases, with lawyers noting the deal is a compromise without admission of liability.